Print Page  Close Window

Press Release

Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)--Sep. 6, 2017-- Ocular Therapeutix™, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, Chief Executive Officer, will present at three upcoming investor conferences in September:

  • Morgan Stanley 15th Annual Global Healthcare Conference
    Fireside Chat: Monday, September 11, 2017 at 1:05 p.m. Eastern Time
    Grand Hyatt New York Hotel, New York, NY
  • Rodman & Renshaw 19th Annual Global Investment Conference
    Presentation: Tuesday, September 12, 2017 at 2:10 p.m. Eastern Time
    Lotte New York Palace Hotel, New York, NY
  • Cantor Fitzgerald 2017 Global Healthcare Conference
    Presentation: Monday, September 25, 2017 at 3:35 p.m. Eastern Time
    InterContinental New York Barclay Hotel, New York, NY

Live audio webcasts of the presentations can be accessed through the Calendar of Events section of the Company's website at investors.ocutx.com. Replays of the webcasts will be available on the Company's website for two weeks following each presentation.

About Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase 3 clinical development for glaucoma and ocular hypertension. The Company’s earlier stage assets include OTX-TIC, a sustained release travoprost intracameral injection for the treatment of moderate to severe glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. These injections include the development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with Regeneron, an extended release protein-based anti-vascular endothelial growth factor (VEGF) trap. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.

Source: Ocular Therapeutix, Inc.

Investors
Burns McClellan
Steve Klass, 212-213-0006
sklass@burnsmc.com
or
Ocular Therapeutix
George Migausky
Interim Chief Financial Officer
gmigausky@ocutx.com
or
Media
Ocular Therapeutix
Scott Corning
Vice President of Marketing & Commercial Operations
scorning@ocutx.com